H.C. Wainwright downgraded Soleno Therapeutics (SLNO) to Neutral from Buy with a price target of $53, down from $100, after the company reached an agreement to be acquired for $53 per share in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- 3 Best Trending Stocks, According to Analysts – 4/7/2026
- Arm downgraded, Arista Networks upgraded: Wall Street’s top analyst calls
- Soleno Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Neurocrine price target raised to $166 from $151 at Wedbush
- Soleno Withdraws EU Application for Prader-Willi Treatment